[Studies on anti-tumor activity of tumor necrosis factor alpha against human renal cell carcinoma cells heterotransplanted into nude mice].
The anti-tumor activity of recombinant tumor necrosis factor alpha (rTNF alpha) against the renal cell carcinoma cell line KU-2 was studied in vivo, employing athymic nude mice. The nude mice were divided into six groups and each group was composed of six mice. Group I underwent no treatment, Groups II and III were injected with 5 and 10 micrograms of rTNF alpha intraperitoneally, respectively. Group IV received 5 micrograms of rTNF alpha intravenously and Groups V and VI were administered 2.5 and 5 micrograms of rTNF alpha six times, given intravenously every other day, respectively. Evaluation of the study was performed according to Battelle Colombus Laboratories Protocol. Tumor regression was defined as RW less than 1; inhibition of tumor proliferation was defined as TRW/CRW less than or equal to 42%. Other results were defined as no effect. No obvious anti-tumor activity was observed in group II and III. Though inhibition of tumor proliferation was noted in Group IV, death of two nude mice in this group was noted. When rTNF alpha was administered to the mice in Group V, complete disappearance of the heterotransplanted tumor in two nude mice and tumor regression in four were observed. No death of mice in this group occurred. When the dose of rTNF alpha was raised to 5 micrograms (Group VI), however, five mice died. The histopathological study revealed remarkable necrosis in the tumor tissue and congestion around the white pulps of the spleen 24 hours after intravenous administration of 5 micrograms of rTNF alpha, although no obvious changes were noted in the liver, kidney and digestive organs.(ABSTRACT TRUNCATED AT 250 WORDS)
Shibayama
T
T
Department of Urology, School of Medicine, Keio University.
Tachibana
M
M
Tazaki
H
H
Nakamura
K
K
D000818:Animals; D002292:Carcinoma, Renal Cell / Q000473:pathology / Q000628:therapy*; D004353:Drug Evaluation, Preclinical; D006801:Humans; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D007680:Kidney Neoplasms / Q000473:pathology / Q000628:therapy*; D008297:Male; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D014183:Transplantation, Heterologous; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage / Q000627:therapeutic use*
D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha